AbbVie's Hopes of Replacing Humira Sales with Rinvoq Gains Momentum for Ulcerative Colitis

AbbVie announced that its Phase III induction study, U-ACHIEVE, of Rinvoq (upadacitinib) in moderate to severe ulcerative colitis, hit the primary endpoint of clinical remission at week 8. It also met all the ranked secondary endpoints.